Form 8-K Rapport Therapeutics, For: Sep 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Rapport Therapeutics terminates stock sales agreement prospectus
September 8, 2025 4:04 PM EDTRapport Therapeutics (NASDAQ: RAPP) terminated its at-the-market sales agreement prospectus effective September 8, 2025, according to a company statement.
The company ended the ATM prospectus filed with its Form S-3 registration statement related to common stock sales under a July 1, 2025 sales agreement with Leerink... More
